BACKGROUND: Our aim was to determine the efficacy of a trivalent inactivated split virus influenza vaccine (TIV) against culture-confirmed influenza A and/or B in adults 18 to 64 years of age during the 2005/2006 season in the Czech Republic. METHODS: 6203 subjects were randomized to receive TIV (N = 4137) or placebo (N = 2066). The sample size was based on an assumed attack rate of 4% which provided 90% power to reject the hypothesis that vaccine efficacy (VE) was > or = 45%. Cases of influenza like illness (defined as fever (oral temperature > or =37.8 degrees C) plus cough and/or sore throat) were identified both by active (biweekly phone contact) and passive (self reporting) surveillance and nasal and throat swabs were collected from subjects for viral culture. RESULTS: TIV was well tolerated and induced a good immune response. The 2005/2006 influenza season was exceptionally mild in the study area, as it was throughout Europe, and only 46 culture-confirmed cases were found in the study cohort (10 influenza A and 36 influenza B). Furthermore among the B isolates, 35 were identified as B/Hong Kong 330/2001-like (B/Victoria/2/87 lineage) which is antigenically unrelated to the vaccine B strain (B/Yamagata/16/88 lineage). The attack rate in the vaccine group (0.7%) was not statistically significantly different from the attack rate in the placebo group (0.9%). CONCLUSION: Due to the atypical nature of the influenza season during this study we were unable to assess TIV efficacy. This experience illustrates the challenge of conducting a prospective influenza vaccine efficacy trial during a single season when influenza attack rates and drift in circulating strains or B virus lineage match can be difficult to estimate in advance. TRIAL REGISTRATION: Clinical trial registery: NCT00197223.

The Vaccination and Travel Medicine Center Hradec Kralove Czech Republic

See more in PubMed

World Health Organization (WHO) Influenza vaccines. Wkly Epidemiol Rec. 2005;80:279–287. PubMed

Advisory Committee on immunization Practices (ACIP) Recommendations of the Advisory Committee on immunization Practices (ACIP) Prevention and control of influenza. Morbidity and Mortality Weekly Report. 2008;57(RR-7) PubMed

Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2004. p. CD001269. PubMed

Rose GW, Cooper CL. Fluarix™, inactivated split-virus influenza vaccine. Expert Opin Biol Ther. 2006;6:301–310. doi: 10.1517/14712598.6.3.301. PubMed DOI

Lin YP, Gregory V, Bennett M, Hay A. Recent changes among human influenza viruses. Virus Res. 2004;103:47–52. doi: 10.1016/j.virusres.2004.02.011. PubMed DOI

Kanegae Y, Sugita S, Endo A, Ishida M, Senya S, Osako K, Nerome K, Oya A. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol. 1990;64:2860–2865. PubMed PMC

Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59–68. doi: 10.1016/0042-6822(90)90186-U. PubMed DOI

Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP. Antigenic and genetic characterization of the hemagglutinin of recent cocirculating strains of influenza B virus. J Gen Virol. 1992;73:2737–2742. doi: 10.1099/0022-1317-73-10-2737. PubMed DOI

Muñoz ET, Deem MW. Epitope analysis for influenza vaccine design. Vaccine. 2005;23:1144–1148. doi: 10.1016/j.vaccine.2004.08.028. PubMed DOI PMC

Ferro VA. Improved design of the annual influenza vaccine using epitope analysis. Expert Review of Vaccines. 2005;4:157–161. doi: 10.1586/14760584.4.2.157. DOI

World health organization (WHO) Recommendations for influenza vaccines. http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/index.html

Langley JM, Faughnan ME. Prevention of influenza in the general population. CMA J. 2004;171:1213–22. PubMed PMC

Skowronski DM, Masaro C, Kwindt TL, Makb A, Petric M, Li Y, Sebastian R, Chonga M, Tame T, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine. 2007;25:2842–2851. doi: 10.1016/j.vaccine.2006.10.002. PubMed DOI

Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest. 2002;22:751–769. doi: 10.2165/00044011-200222110-00004. DOI

Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, Innis BL. Rapid licensure of a new, inactivated influenza vaccine in the United States. Human Vaccine. 2005;1:239–244. PubMed

Jefferson T. Influenza vaccination: policy versus evidence. BMJ. 2006;333:912–915. doi: 10.1136/bmj.38995.531701.80. PubMed DOI PMC

Centers for Disease Control and Prevention (CDC) Overview of influenza surveillance in the United States. http://www.cdc.gov/flu/weekly/fluactivity.htm

Harmon MW. In: Laboratory Diagnosis of Viral Infections. 2. Lennette EH, editor. Marcel Dekker, NY, USA; 1992. Influenza Viruses; pp. 515–534.

Manuguerra JC, Hannoun C. Influenza and Other Respiratory Diseases Surveillance and Laboratory Diagnosis. Inst Pasteur Coll Lab Refer Exper. 1999. pp. 186–189.

Waris M, Ziegler T, Kivivirta M, Ruuskanen O. Rapid detection of respiratory syncytial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies. J Clin Microbiol. 1990;28:1159–1162. PubMed PMC

Greenwood M, Yule GU. The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med. 1915;8(part 2):113–94. PubMed PMC

European Committee for Medicinal Products for Human Use. Note for guidance on harmonization of requirements for influenza vaccines, March 1997 (CPMP/BWP/214/96) European Agency for the Evaluation of Medicinal Products.

US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. 2007.

Jefferson T, Rivetti D, Di C, Pietrantonj C, Rivetti A, Demicheli V. Vaccines for Preventing Influenza in Healthy Adults. Cochrane Database Syst Rev. 2007. p. CD001269. PubMed

Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated Vaccines Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated Vaccines. New Eng J Med. 2006;355:2513–2522. doi: 10.1056/NEJMoa061850. PubMed DOI PMC

Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS. Prevention of symptomatic seasonal infuenza in 2005 ± 2006 by inactivated and live attenuated vaccines. J Infect Dis. 2008;198(3):312–317. doi: 10.1086/589885. PubMed DOI PMC

Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Keraney DH, Colborn DK, Kurs-Lasky M, Harslsm MA, Byers CJ, Zoffel LM, Fabian IA, Bernard BS, Kerr JD. Effectiveness of an inactivated influenza vaccine in preventing accute otitis media in young children: a randomized controlled trial. JAMA. 2003;290(12):1608–1616. doi: 10.1001/jama.290.12.1608. PubMed DOI

Meijer A, Meerhoff TJ, Meuwissen LE, Velden J van der, Paget WJ. Epidemiological and virological assessment of influenza activity in Europe during winter 2005–2006. Euro Surveill. 2007;12(9):E11–2. PubMed

European Influenza Surveillance Scheme. Weekly total ILI morbidity per 100000 population. The Czech Republic. EISS Weekly Electronic Bulletin 2006. 2006. p. 157.http://www.eiss.org/cgi-files/figures2002.cgi?year=2006&week=16&region=Czech+Republic&type=c (Accessed 09 January 2009).

European Influenza Surveillance Scheme. Weekly total acute respiratory infections morbidity per 100000 population. The Czech Republic. EISS Weekly Electronic Bulletin 2006. 2006. p. 157.http://www.eiss.org/cgi-files/figures2002.cgi?year=2006&week=16&region=Czech+Republic&type=c1

McCullers JA, Saito T, Iverson AR. Multiple Genotypes of Influenza B Virus Circulated between 1979 and 2003. J Virol. 2004;78:12817–12828. doi: 10.1128/JVI.78.23.12817-12828.2004. PubMed DOI PMC

Aguilera JF, Paget WJ, Mosnier A, Heijnen ML, Uphoff H, Velden J van der, Vega T, Watson JM. Heterogenous case definitions used for the surveillance of influenza in Europe. Eur J Epidemiol. 2003;18:751–754. doi: 10.1023/A:1025337616327. PubMed DOI

Hannoun C. Case definition for influenza surveillance. Eur J Epidemiol. 2003;18:737–738. doi: 10.1023/A:1025300118935. PubMed DOI

Nichol KL. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine. 2006;24:6726–6728. doi: 10.1016/j.vaccine.2006.05.064. PubMed DOI

Zambon M, Hays J, Webster A, Newman R, Keene O. Diagnosis of influenza in the community-Relationship of clinical diagnosis to confirmed virological, serological, or molecular detection of influenza. Arch Intern Med. 2001;161:2116–2122. doi: 10.1001/archinte.161.17.2116. PubMed DOI

Gooskens J, Swaan CM, Claas ECJ, Kroes ACM. Rapid molecular detection of influenza outbreaks in nursing homes. J Clin Virol. 2008;41:7–12. doi: 10.1016/j.jcv.2007.10.023. PubMed DOI

World Health Organization (WHO) Recommended composition of influenza virus vaccines for use in the 2006–2007 influenza season. 2007. http://www.who.int/entity/csr/disease/influenza/2007northreport.pdf

Barr IG, Komadina N, Durrant C, Sjogren H, Hurt AC, Shaw RP. Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell. 2006;30:350–357. PubMed

Levandowski RA, Regnery HL, Staton E, Burgess BG, Williams MS, Groothuis JR. Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics. 1991;88:1031–1036. PubMed

Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A. Cross-protection against homologous drift variants of Influenza A and B after vaccination with split vaccine. Intervirology. 2007;50:58–62. doi: 10.1159/000096314. PubMed DOI

Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

See more in PubMed

ClinicalTrials.gov
NCT00197223